Owing to the key role of this protein family as regulator of apoptosis, indirectly targeting NF-κB by blocking anti-apoptotic effectors could be a potential therapeutic strategy in order to improve patient outcomes, as well as to overcome resistance in relapsed/refractory cancer when used in combination with radiotherapy or chemotherapy [8]. The gene discussed is NFKB1; the disease is cancer.